[go: up one dir, main page]

WO2009035307A3 - Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain - Google Patents

Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain Download PDF

Info

Publication number
WO2009035307A3
WO2009035307A3 PCT/KR2008/005439 KR2008005439W WO2009035307A3 WO 2009035307 A3 WO2009035307 A3 WO 2009035307A3 KR 2008005439 W KR2008005439 W KR 2008005439W WO 2009035307 A3 WO2009035307 A3 WO 2009035307A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
preparing
novel compounds
composition
inhibiting pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/005439
Other languages
French (fr)
Other versions
WO2009035307A2 (en
Inventor
Choo Hae-Young Park
Heung Sik Na
Hyewhon Rhim
Yoo Lim Kam
Seung Keun Back
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Publication of WO2009035307A2 publication Critical patent/WO2009035307A2/en
Publication of WO2009035307A3 publication Critical patent/WO2009035307A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel compounds, a process for preparing the same, and a pain relief composition, comprising the same. The compound of the present invention has excellent inhibitory effect on T-type calcium channel activity, and chronic neuropathic and inflammatory pain, thereby being used to relieve pain.
PCT/KR2008/005439 2007-09-14 2008-09-12 Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain Ceased WO2009035307A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0093694 2007-09-14
KR1020070093694A KR101079459B1 (en) 2007-09-14 2007-09-14 Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain

Publications (2)

Publication Number Publication Date
WO2009035307A2 WO2009035307A2 (en) 2009-03-19
WO2009035307A3 true WO2009035307A3 (en) 2009-05-07

Family

ID=40452722

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005439 Ceased WO2009035307A2 (en) 2007-09-14 2008-09-12 Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain

Country Status (2)

Country Link
KR (1) KR101079459B1 (en)
WO (1) WO2009035307A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101705718B1 (en) * 2013-12-30 2017-02-14 이화여자대학교 산학협력단 Novel amide derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of pain containing the same as an active ingredient
DK3364993T3 (en) 2015-10-22 2023-01-09 Cavion Inc APPROACHES TO THE TREATMENT OF ANGELMAN SYNDROME
CN110545806A (en) 2017-02-15 2019-12-06 卡维昂公司 calcium channel inhibitor
MX2019012818A (en) 2017-04-26 2020-07-14 Cavion Inc METHODS TO IMPROVE MEMORY AND COGNITION AND FOR THE TREATMENT OF MEMORY AND COGNITIVE DISORDERS.
US12528772B2 (en) 2019-07-11 2026-01-20 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
WO2025255502A1 (en) 2024-06-07 2025-12-11 Cavion, Inc. PYRIDYL AMIDE Cav3 CHANNEL MODULATORS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214766A (en) * 1984-04-04 1985-10-28 Terumo Corp Amide derivative and 5-lipoxigenase inhibitor containing said derivative as active component
US4675319A (en) * 1985-06-20 1987-06-23 Recordati S. A. Chemical And Pharmaceutical Company Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use
US6420560B1 (en) * 1999-06-07 2002-07-16 Theravance, Inc. H1—histamine receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60214766A (en) * 1984-04-04 1985-10-28 Terumo Corp Amide derivative and 5-lipoxigenase inhibitor containing said derivative as active component
US4675319A (en) * 1985-06-20 1987-06-23 Recordati S. A. Chemical And Pharmaceutical Company Antianaphylactic and antibronchospastic piperazinyl-(N-substituted phenyl)carboxamides, compositions and use
US6420560B1 (en) * 1999-06-07 2002-07-16 Theravance, Inc. H1—histamine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOO LIMKAM ET AL.: "Solution-phase combinatorial synthesis of nonpeptide bradykinin antagonists", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 3543 - 3552 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US12383539B2 (en) 2018-10-03 2025-08-12 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Also Published As

Publication number Publication date
WO2009035307A2 (en) 2009-03-19
KR101079459B1 (en) 2011-11-03
KR20090028239A (en) 2009-03-18

Similar Documents

Publication Publication Date Title
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
WO2009035307A3 (en) Novel compounds, process for preparing the same, and composition comprising the same for inhibiting pain
WO2008127646A8 (en) Transaminase-based processes for preparation of pregabalin
WO2009043889A3 (en) Oxadiazole derivatives
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2008146174A3 (en) Use of compounds having a monogalactosyldiacylglycerol synthase inhibitory activity as herbicide or algaecide, herbicide and algaecide compositions
WO2009146540A8 (en) N-piperidinyl acetamide derivatives as calcium channel blockers
WO2008112199A8 (en) Method for inhibiting topoisomerase ii
WO2008070016A3 (en) Inhibitors of akt activity
WO2006091395A3 (en) Inhibitors of akt activity
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
WO2009147205A3 (en) Synergistic fungicidal mixtures
WO2008070268A3 (en) Pharmaceutical compositions
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2009012242A3 (en) Sodium channel inhibitors
WO2006135627A3 (en) Inhibitors of akt activity
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2007133562A3 (en) Monocyclic heteroaryl compounds
WO2011149288A3 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2008033449A3 (en) Compounds for the treatment of angiogenesis
WO2006110638A3 (en) Inhibitors of akt activity
TW200736226A (en) Novel histidine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831217

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831217

Country of ref document: EP

Kind code of ref document: A2